We can’t show the full text here under this license.
Abstract
Lipid nanoparticles (LNPs) are highlighted for their superior delivery efficiency and biocompatibility in nucleic acid therapies.
- Nucleic acid-based therapies are being explored for gene regulation and therapeutic protein production for various diseases.
- Challenges in clinical application include high molecular weight, limited cellular uptake, and vulnerability to enzymatic degradation.
- LNPs demonstrate significant advantages over other delivery vectors due to their customizable design and efficiency.
- The FDA-approved siRNA drug Onpattro® serves as a key example of successful LNP application in clinical settings.
- The review discusses recent advancements in LNP design and mechanisms, aiming to clarify their roles in overcoming delivery barriers.
Simplified